Parkinsonism in patients with chronic hepatitis C treated with interferon-α2b: a report of two cases

被引：8
|
作者：
Kajihara, Mikio [1 ]
Montagnese, Sara [1 ,3 ]
Khanna, Pooja [1 ]
Amodio, Piero [3 ]
Schapira, Anthony H. V. [2 ]
Dusheiko, Geoffrey M. [1 ]
Morgan, Marsha Y. [1 ]
机构：
[1] UCL, Ctr Hepatol, Dept Med, Sch Med, London NW3 2PF, England
[2] UCL, Univ Dept Clin Neurosci, Univ Coll London Med Sch, London NW3 2PF, England
[3] Univ Padua, Clin Med V, Dept Clin & Expt Med, I-35100 Padua, Italy
来源：
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 2010年 / 22卷 / 05期
关键词：
hepatitis C virus; interferon; Parkinsonism; DRUG-INDUCED PARKINSONISM; TUMOR-NECROSIS-FACTOR; ALPHA; THERAPY; PEGINTERFERON; PERSISTENT; RIBAVIRIN;
D O I：
10.1097/MEG.0b013e32833383e3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Details of two patients with chronic hepatitis C infection who developed features of Parkinsonism when treated with IFN-alpha 2b and ribavirin are reported. The symptoms resolved when treatment was discontinued in one patient but not in the other. Physicians should be alert to the possibility that drug-related Parkinsonism may complicate treatment of hepatitis C infection with antiviral agents; the agent most likely responsible is IFN-alpha 2b. Prompt withdrawal of treatment is mandatory but does not always guarantee reversal of the Parkinsonian features. Eur J Gastroenterol Hepatol 22:628-631 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码：628 / 631
页数：4
相关论文
共 50 条
  • [1] Escalating interferon-α-2b dose for patients with chronic hepatitis C
    De La Riva, E
    Garcia-Carrasquillo, RJ
    Puppo, MD
    Mustacchia, PJ
    Factor, S
    Joe, A
    Finegold, J
    Riley, TH
    Sarabanchong, V
    Ligresti, RJ
    Markowitz, DD
    McMahon, DJ
    Magun, AM
    Worman, HJ
    HEPATO-GASTROENTEROLOGY, 1998, 45 (24) : 2308 - 2314
  • [2] Interferon-β induction/interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C
    Kim, KI
    Sasase, N
    Taniguchi, M
    Mita, K
    Kinoshita, K
    Togitani, T
    Shikata, M
    Kimura, N
    Izawa, S
    Ohtani, A
    Nakao, K
    Muramoto, Y
    Kim, SR
    Nabeshima, S
    Ishii, F
    Tanaka, K
    Hayashi, Y
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 2005, 25 (02) : 71 - 76
  • [3] Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C
    Dettmer, RM
    Reinus, JF
    Clain, DJ
    Aytaman, A
    Levendoglu, H
    Bloom, AA
    Isaacson, MP
    Spinnell, M
    Meyer, D
    Sarabanchong, V
    Zhang, YT
    Garcia-Carrasquillo, RJ
    Markowitz, DD
    Magun, AM
    Worman, HJ
    HEPATO-GASTROENTEROLOGY, 2002, 49 (45) : 758 - 763
  • [4] Sarcoidosis, chronic hepatitis C and interferon-α:: Two cases
    Luchi, S
    Scasso, A
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 (10) : 775 - 776
  • [5] Histological and virological long-term outcome in patients treated with interferon-α2b and ribavirin for chronic hepatitis C
    Schvarcz, R
    Glaumann, H
    Reichard, O
    Weiland, O
    JOURNAL OF VIRAL HEPATITIS, 1999, 6 (03) : 237 - 242
  • [6] Superiority of standard interferon-α2b compared to pegylated interferon-α2b (12 kDa) in a hemodialysis patient with chronic hepatitis C?
    Potthoff, A
    Wiegand, J
    Lüth, JB
    Wedemeyer, H
    Manns, MR
    Tillmann, HL
    CLINICAL NEPHROLOGY, 2005, 63 (03) : 232 - 235
  • [7] Efficacy of hepatitis B vaccination and interferon-α-2b combination therapy versus interferon-α-2b monotherapy in children with chronic hepatitis B
    Helvaci, M
    Kizilgunesler, A
    Kasirga, E
    Ozbal, E
    Kuzu, M
    Sozen, G
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (07) : 785 - 791
  • [8] Suicidal ideation during interferon-α2b and ribavirin treatment of patients with chronic hepatitis C
    Dieperink, E
    Ho, SB
    Tetrick, L
    Thuras, P
    Dua, K
    Willenbring, ML
    GENERAL HOSPITAL PSYCHIATRY, 2004, 26 (03) : 237 - 240
  • [9] Differential Antiviral Effects of Pegylated Interferon-α2a and Pegylated Interferon-α2b in Chronic Hepatitis C
    Durante-Mangoni, Emanuele
    Parrella, Antonio
    Iossa, Domenico
    Andini, Roberto
    Molaro, Rosa
    Battimelli, Carminia
    Sodano, Giuseppe
    Utili, Riccardo
    CLINICAL DRUG INVESTIGATION, 2014, 34 (12) : 871 - 878
  • [10] Differential Antiviral Effects of Pegylated Interferon-α2a and Pegylated Interferon-α2b in Chronic Hepatitis C
    Emanuele Durante-Mangoni
    Antonio Parrella
    Domenico Iossa
    Roberto Andini
    Rosa Molaro
    Carminia Battimelli
    Giuseppe Sodano
    Riccardo Utili
    Clinical Drug Investigation, 2014, 34 : 871 - 878
12345